HIGH PREVALENCE OF OVERWEIGHT AND OBESITY IN POST-MENOPAUSAL BREAST CANCER PATIENTS WITH LUMINAL SUBTYPE IN USE OF CURATIVE HORMONIOTHERAPY (HT)

Introduction: Recent studies have shown that a high body mass index (BMI) ( > 24 kg / m2) influences the prognosis of breast cancer patients and the choice of medication in patients with BMI > 30 kg/m2. Objective: To determine the prevalence of obese patients with breast cancer based on BMI and to evaluate if there is a difference in the distribution of the overweight population according to the immunohistochemical classification (IHC), menopausal status or treatment modality instituted at the Regional Hospital of Taguatinga (HRT) Method: Analysis based on the database from 11/02/12 to 11/06/19 of patients with breast cancer treated in HRT. Evaluation of the prevalence of overweight / obesity in these patients and stratification of the data according to IHC classification, menopausal status and treatment modality. Results: Among 3325 patients treated on HRT, 714 (21.5%) are women with breast cancer with a mean age of 53 years +/- 14 years. Regarding weight, only 18% were at ideal weight. In relation to the IHC classification, only 478 (67%) were ductal or lobular carcinomas with complete IHC panel, being 72.6% luminal, 10.8% triple-negative, 10.6% RH+HER2+ and 5.9% RH-Her2+. The majority of patients started treatment with HT (64%) mainly for curative purposes (82.5%) and 63% were in postmenopausal period. We observed an 83% overweight / obesity rate independent of the IHC panel with mean BMI of 28.9 kg/m2 +/- 4. The prevalence of overweight / obesity was 88% in those patients with RH-HER2 + and 86% in those classified as luminal. Regarding menopausal status, 85% of postmenopausal patients (63% of patients) are overweight, while 72% are overweight in premenopausal women (15% of patients ). Finally, regarding the type of treatment, prevalence of overweight / obesity was observed in 82% of patients on adjuvant HT and 84% in those in palliative HT. In addition, 56% of all patients are using HT, 90% of which with curative purpose. Conclusion: Most patients (83%) are overweight. Furthermore, most of these patients are in menopause period, using curative hormone therapy and express IHC panel compatible with luminal, making this finding more worrying. Thus, more active weight management strategies and medications in overweight / obese patients are necessary.